Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688382.SS
STRONG SELLREMOVEInventisBio Co., Limited · Healthcare · China · $1.7B · Avg Vol: $36M/d
InventisBio is a clinical-stage biotech firm. It does not possess the validated, high-utilization manufacturing capabilities of a CDMO, making it a capital-intensive drug developer rather than a CDMO pricing power beneficiary.
COMPANY DESCRIPTION
InventisBio Co., Limited is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class small molecule drugs for oncology and metabolic diseases. The company's competitive moat is anchored by its proprietary drug discovery platform and high-potential pipeline, including advanced EGFR and estrogen receptor inhibitors. It is a research-driven biotech player with a business model that combines domestic commercialization partnerships with global out-licensing strategies.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 27M | 25M | 6M | -55.2% |
| EPS | -0.14 | -0.07 | -0.06 | -0.08 | — |
| Shares | 575M | 575M | 577M | 578M | +0.6% |
| Debt | 4M | 2M | 4M | 3M | -6.9% |
| Equity | 327M | 295M | 268M | 227M | -11.5% |
| Op CF | -70M | -45M | -36M | -23M | — |
| Inv CF | -1M | -103M | -8M | -4M | — |
| Fin CF | 292M | -2M | -957,896 | -919,324 | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688382.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688382.SS | InventisBio Co., Limited(you) | $1.7B | 12 | STRONG SELL |
| 2616.HK | CStone Pharmaceuticals | $1.6B | 14 | STRONG SELL |
| 688443.SS | Chongqing Genrix Biopharmaceutical Co., Ltd. | $1.5B | 12 | STRONG SELL |
| 300204.SZ | Staidson (Beijing) BioPharmaceuticals Co., Ltd. | $1.8B | 16 | STRONG SELL |
| 688068.SS | Beijing Hotgen Biotech Co., Ltd. | $1.2B | 12 | STRONG SELL |
| 300294.SZ | China Resources Boya Bio-pharmaceutical Group Co.,Ltd | $1.2B | 16 | STRONG SELL |
| 2595.HK | GenFleet Therapeutics (Shanghai) Inc. | $1.6B | 21 | SELL |
| 9606.HK | Duality Biotherapeutics, Inc. | $2.6B | 11 | STRONG SELL |
| 2617.HK | TransThera Sciences (Nanjing), Inc. | $1.8B | 4 | STRONG SELL |
| 6855.HK | Ascentage Pharma Group International | $1.9B | 4 | STRONG SELL |
Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%